Berg as President and CEO, effective 1 January 2012.
Berg brings 30 years of experience in strategic leadership, organizational growth and relationship-building, having served as executive director/CEO of the Society of Manufacturing Engineers (SME) and, most recently, as the founder and owner of three small businesses and consultant to both non-profits and for-profits.
At the helm of SME, Berg led the development of SME's strategic plan, Plan 2010, and the expansion of its technical networks. Through these and other forward-thinking initiatives, she prepared the organization for changes in industry business models, competitive forces and the impact of globalization.
Berg's selection by the SME Board of Directors as executive director in 2000 made her the youngest person to head a global engineering/technical organization at the time. Prior to that, she held other domestic and international positions where she gained experience that will also benefit ISPE. For example, she facilitated dialogue, joint ventures and coalitions with other trade groups, associations, companies, governments and agencies. She brings to ISPE these relationship-building skills and links to industries and associations
“Berg's demonstrated ability to anticipate industry changes, set a vision for success, then lead coordinated, dynamic efforts to achieve this plan make her the ideal person to drive us in achieving our mission,” said 2012 ISPE Board Chairman Arthur “Randy” Perez.
“As the voice of pharmaceutical engineering and manufacturing communities, ISPE is dedicated to working with Members and their companies to resolve issues and drive their understanding and use of next-generation manufacturing practices,” continued Perez. “Berg's appointment comes at a time when the global pharmaceutical industry faces increased pressure to improve productivity and control costs across their product development and manufacturing operations. She brings the right blend of knowledge and leadership experience to guide us in enhancing our value to our Members, our relevance to the industry, and our role as a catalyst for solutions that will positively influence global health.”
Berg replaces Bob Best, who resigned his position effective 31 December after a 27-year career with the society. Best will remain involved in the organization as a consultant through the end of 2012.
Berg brings 30 years of experience in strategic leadership, organizational growth and relationship-building, having served as executive director/CEO of the Society of Manufacturing Engineers (SME) and, most recently, as the founder and owner of three small businesses and consultant to both non-profits and for-profits.
At the helm of SME, Berg led the development of SME's strategic plan, Plan 2010, and the expansion of its technical networks. Through these and other forward-thinking initiatives, she prepared the organization for changes in industry business models, competitive forces and the impact of globalization.
Berg's selection by the SME Board of Directors as executive director in 2000 made her the youngest person to head a global engineering/technical organization at the time. Prior to that, she held other domestic and international positions where she gained experience that will also benefit ISPE. For example, she facilitated dialogue, joint ventures and coalitions with other trade groups, associations, companies, governments and agencies. She brings to ISPE these relationship-building skills and links to industries and associations
“Berg's demonstrated ability to anticipate industry changes, set a vision for success, then lead coordinated, dynamic efforts to achieve this plan make her the ideal person to drive us in achieving our mission,” said 2012 ISPE Board Chairman Arthur “Randy” Perez.
“As the voice of pharmaceutical engineering and manufacturing communities, ISPE is dedicated to working with Members and their companies to resolve issues and drive their understanding and use of next-generation manufacturing practices,” continued Perez. “Berg's appointment comes at a time when the global pharmaceutical industry faces increased pressure to improve productivity and control costs across their product development and manufacturing operations. She brings the right blend of knowledge and leadership experience to guide us in enhancing our value to our Members, our relevance to the industry, and our role as a catalyst for solutions that will positively influence global health.”
Berg replaces Bob Best, who resigned his position effective 31 December after a 27-year career with the society. Best will remain involved in the organization as a consultant through the end of 2012.
Companies in this press-release
